Targeting pain mechanisms from the 'top-down' and the 'bottom-up' in chronic tension-type headache

Not Applicable

Completed

• Conditions: Chronic tension-type headache; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12614000091606
• Lead Sponsor: Dr Siobhan Schabrun

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Participants with a diagnosis of chronic tension-type headache (CCTH) according to the international Classification of Headache Disorders, 2nd edition (ICHD-II) criteria will be recruited. Additional inclusion criteria will comprise: i) diagnosis of CTTH for greater than 12 months prior to commencing the trial, ii) experience painful episodes on 15 or more days per month, iii) experience painful episodes that last more than 4 hours when untreated, and iv) experienced symptom onset before age 50 years.

Exclusion Criteria

Individuals under 18 years or who present with neurological or psychiatric conditions or use of prophylactic migraine drugs will be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Perceived response to therapy will be assessed using a 7 point Likert scale ranging from completely recovered to vastly worsened (Global Perceived Effect Scale (GPES)).[Assessed at baseline and immediately following the 5-treatment intervention. ];Safety and adverse events: data on any side effects or adverse events (such as headache, nausea, dizziness) will be recorded. [Assessed at baseline and immediately following the 5-treatment intervention. ];Headache intensity, frequency, duration and use of analgesics: Headache intensity will be recorded on a 10 cm visual analogue scale (VAS) with 'no pain' at zero and 'worst pain imaginable' at 10, headache duration as hours per day, frequency as the number of days with headache per month, and use of analgesics as the number of doses. [Assessed immediately before treatment and immediately after treatment over a 4-week period using responses to a daily, automated SMS system. <br>]